Replies to post #2262 on Iovance Biotherapeutics Inc (IOVA)

[dstock07734]

Read this paper which is about old version of DCVax-L on treating 11 types of difficult pediatric cancers. I simply cannot see $IOVA has a bright future.

Personalized dendritic cell vaccine in multimodal individualized combination therapy improves survival in high-risk pediatric cancer patients
https://onlinelibrary.wiley.com/doi/full/10.1002/ijc.35062

We analyzed data from all consecutive patients who received personalized DC vaccine between 2016 and 2022. Inclusion criteria were children and young adults, aged 0–20 years at diagnosis with relapsed/refractory and/or metastasizing high-risk solid tumors diagnosed in 2005–2021, who received at least two doses of DC vaccine as part of multimodal individualized combination treatment and who signed (or whose legal guardians signed) an informed consent.

We observed repeated recurrences or progressions, however, with favorable overall survival. Three- and five-year overall survival was 80.8% and 60.2%, and 60.4% and 30.2%, respectively, when calculated from the first progression. This is a notable outcome for such a high-risk cohort in comparison to historical data,21–26 where 3-year survival ranged from 15% to 30% and 5-year survival was generally <15% from recurrence

[Roblok]

Thank you for your reply. With Q1 result will be announced in a few hours, let's see how the market reponds. GL